Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Xylazine Outreach Treatment topic

No spam. Unsubscribe anytime.

Mass. xylazine working group pushes training, wound-care access and coordinated outreach ahead of Dec. 11 presentation

Special Commission on Xylazine (working group on outreach and treatment) · November 18, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

A Special Commission on Xylazine working group heard clinicians, law-enforcement trainers and harm-reduction providers describe gaps in training, wound care and continuity after hospital discharge and set deadlines for research and a Dec. 11 presentation to the full commission.

The Special Commission on Xylazine’s working group on outreach and treatment met to map gaps in education, wound care and service access for people exposed to xylazine and assigned follow-up research ahead of a Dec. 11 presentation to the full commission.

"Substance use disorder in general is one of my priorities," said Representative Kate Donahue (19th Worcester District), who urged the commission to increase education about xylazine and ensure treatment facilities have training to manage wounds and refer patients when higher-level care is needed. Donahue also said stigma is a major barrier, noting her personal loss in a reminder that family supports matter in outreach design.

Angela Davis, assistant under secretary for law enforcement and criminal justice in the Executive Office of Public Safety and Security, described statewide virtual and in-person trainings for first responders and said recruit and in‑service curricula at the Municipal Police Training Committee include xylazine. "We had an excess of 350 or 400 individuals tap into that first training," Davis said, arguing more, accessible trainings would help first responders and community clinicians recognize and respond to xylazine exposure.

Clinicians urged broader education and more consistent wound-care protocols. "Harm reduction programs have learned about xylazine and have been trained and have developed protocols," said Dr. Simeon Kimmel, an infectious-disease and addiction-medicine specialist who works with drop-in sites in Boston. Kimmel said those programs often need additional trained personnel, more advanced wound-care supplies and longer windows of availability. He described typical self-care wound kits as including sterile water, alcohol swabs, bacitracin, Band‑Aids, gauze and gloves, and said such kits can help early-stage ulcers but are not sufficient for complex or deep wounds.

Dr. David McGarry, medical director of the Office of Inpatient Management at the Department of Mental Health, highlighted inpatient gaps: xylazine exposure can complicate withdrawal and make initiation of methadone or buprenorphine more difficult. He asked whether medications such as clonidine should be used more often to mitigate withdrawal symptoms during hospitalization so patients can receive both infection care and substance‑use treatment while hospitalized.

Speakers identified three overlapping populations for outreach: people not yet exposed to xylazine (prevention education); people who have been exposed and need wound-care and medical follow-up; and people engaged with services who need better support to initiate or stay in substance‑use treatment. Members discussed geospatial analyses to locate service gaps and emphasized the need for coordinated messaging across family-support groups, harm-reduction organizations and public-health programs to reduce stigma and standardize guidance.

Participants agreed on next steps and deadlines. Commission staff will distribute meeting notes and a draft slide deck; the working group asked members to send materials by Dec. 2, staff will circulate a draft PowerPoint by Dec. 4 and members were asked to return edits by Dec. 9 ahead of the Dec. 11 full commission meeting. Several members volunteered for follow-up work: Dr. McGarry will examine the cost‑effectiveness of wound‑care kits; Representative Donahue offered to contact family-support organizations; Undersecretary Davis will follow up on incarcerated-population outreach; and Dr. Kimmel will look at travel‑distance data to identify geographic gaps in service coverage.

The transcript provided no meeting date; organizers set the operational deadlines above in the session and scheduled the full-commission presentation for Dec. 11. The working group adjourned at 9:55 a.m. after a motion to adjourn was made and accepted.

What happens next: the working group will compile submitted materials into presentation slides for the commission’s Dec. 11 meeting and pursue the research assignments noted above.